Natural history of pediatric Crohn's disease: A population-based cohort study

被引:481
作者
Vernier-Massouille, Gwenola [1 ]
Balde, Mamadou [2 ]
Salleron, Julia [3 ]
Turck, Dominique [4 ]
Dupas, Jean Louis [5 ]
Mouterde, Olivier [6 ]
Merle, Veronique [6 ]
Salomez, Jean Louis [2 ]
Branche, Julien [1 ]
Marti, Raymond [2 ]
Lerebours, Eric [6 ]
Cortot, Antoine [1 ]
Gower-Rousseau, Corinne [2 ]
Colombel, Jean Frederic [1 ]
机构
[1] Ctr Hosp Reg & Univ Lille, Hop Claude Huriez, Dept Hepatogastroenterol, Serv Hepatogastroenterol,Registre Malad Inflammat, F-59037 Lille, France
[2] Hop Calmette, Serv Epidemiol & Sante Publ, EPIMAD, Lille, France
[3] Fac Med, Biostat Unit, CERIM, Lille, France
[4] Hop Jeanne Flandre, Pediat Clin, EPIMAD, Lille, France
[5] Hop Nord Amiens, Ctr Amiens, EPIMAD, Amiens, France
[6] Rouen Univ Hosp, Ctr Rouen, EPIMAD, Rouen, France
关键词
D O I
10.1053/j.gastro.2008.06.079
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The natural history of pediatric Crohn's disease and risk factors necessitating surgery have not been thoroughly described. Methods: In a geographically derived incidence cohort diagnosed from 1988 to 2002, we identified 404 Crohn's disease patients (ages, 0-17 years at diagnosis) with a follow-up time :2 years. Results: Median follow-up time was 84 months (range, 52124 months). The most frequent disease location at diagnosis was the terminal ileum/colon (63%). Follow-up was characterized by disease extension in 31% of children. Complicated behavior was observed in 29% of children at diagnosis and 59% at follow-up. Kaplan-Meier survival estimates of the cumulative incidence of surgery were 20% at 3 years and 34% at 5 years from diagnosis. Multivariate Cox models showed that both structuring behavior at diagnosis (hazard ratio [HR], 2.54; 95% confidence interval [CI]: 1.58 - 4.01) and treatment with corticosteroids (HR, 2.98; 95% CI: 1.64 - 5.41) were associated with increased risk for surgery, whereas treatment with azathioprine (HR, 0.51; 95% CI: 0.33 - 0.78) was associated with decreased risk. Azathioprine was introduced earlier in the course of disease in patients not undergoing surgery than in patients requiring surgery. Conclusions: Pediatric Crohn's disease was characterized by frequent occurrence, with time, of a severe phenotype with extensive, complicated disease. Immunosuppressive therapy may improve the natural history of this disease and decrease the need for performing surgery.
引用
收藏
页码:1106 / 1113
页数:8
相关论文
共 48 条
[1]   Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease [J].
Agrawal, A ;
Durrani, S ;
Leiper, K ;
Ellis, A ;
Morris, AI ;
Rhodes, JM .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (12) :1215-1220
[2]   Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease [J].
Akobeng, AK ;
Gardener, E .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[3]   Incidence of juvenile-onset Crohn's disease in Scotland: Association with northern latitude and affluence [J].
Armitage, EL ;
Aldhous, MC ;
Anderson, N ;
Drummond, HE ;
Riemersma, RA ;
Ghosh, S ;
Satsangi, J .
GASTROENTEROLOGY, 2004, 127 (04) :1051-1057
[4]   Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease:: A prospective population-based study in northern France (1988-1999) [J].
Auvin, S ;
Molinié, T ;
Gower-Rousseau, T ;
Brazier, F ;
Merle, V ;
Grandbastien, B ;
Marti, R ;
Lerebours, I ;
Dupas, JTL ;
Colombel, JF ;
Salomez, JL ;
Cortot, A ;
Turck, D .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (01) :49-55
[5]   Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease [J].
Baldassano, R ;
Braegger, CP ;
Escher, JC ;
DeWoody, K ;
Hendricks, DF ;
Keenan, GF ;
Winter, HS .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (04) :833-838
[6]   Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study [J].
Baron, S ;
Turck, D ;
Leplat, C ;
Merle, V ;
Gower-Rousseau, C ;
Marti, R ;
Yzet, T ;
Lerebours, E ;
Dupas, JL ;
Debeugny, S ;
Salomez, JL ;
Cortot, A ;
Colombel, JF .
GUT, 2005, 54 (03) :357-363
[7]  
BARTON JR, 1990, Q J MED, V75, P423
[8]   INCIDENCE OF INFLAMMATORY BOWEL-DISEASE IN SCOTTISH CHILDREN BETWEEN 1968 AND 1983 - MARGINAL FALL IN ULCERATIVE-COLITIS, 3-FOLD RISE IN CROHNS-DISEASE [J].
BARTON, JR ;
GILLON, S ;
FERGUSON, A .
GUT, 1989, 30 (05) :618-622
[9]   A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease [J].
Cezard, JP ;
Nouaili, N ;
Talbotec, C ;
Hugot, JP ;
Gobert, JG ;
Schmitz, J ;
Mougenot, JF ;
Alberti, C ;
Goulet, O .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2003, 36 (05) :632-636
[10]   CORTICOSTEROID OR CORTICOTROPHIN THERAPY IN CROHNS DISEASE (REGIONAL-ENTERITIS) [J].
COOKE, WT ;
FIELDING, JF .
GUT, 1970, 11 (11) :921-+